AbbVie Inc.
ABBV● 市場休市$263.37-1.09%
HealthcareP/E 74.2股息 2.59%📅 財報 10月30日
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines.
價格圖表
右方向鍵：此組的更多工具
右方向鍵：此組的更多工具
右方向鍵：此組的更多工具
右方向鍵：此組的更多工具
右方向鍵：此組的更多工具
右方向鍵：此組的更多工具
右方向鍵：此組的更多工具
載入圖表中…
概覽
形態分析 (Basic+)
K線形態識別在 Basic 及以上方案中可用。 升級
關於 AbbVie Inc.
AbbVie Inc.（ABBV）屬於 Healthcare 板塊（Drug Manufacturers - General）。 該股在 NYSE 上市。 市值：$4651.1億。 52 周區間：$190.75 – $269.39。
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines.
閱讀更多
Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients.
Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection.